Strides Pharma relaunches Ranitidine tablets in US

The company had suspended sales of its generic Ranitidine tablets after the USFDA found contamination in some Ranitidine tablets sold by various companies with potentially cancer causing impurities, NDMA. Strides said now the drug meets the limits prescribed by the US drug regulator.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news